William Blair upgraded shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) from a market perform rating to an outperform rating in a research note issued to investors on Monday, MarketBeat Ratings reports. William Blair also issued estimates for Arrowhead Pharmaceuticals’ Q1 2018 earnings at ($0.11) EPS, Q2 2018 earnings at ($0.19) EPS, Q3 2018 earnings at ($0.19) EPS and Q4 2018 earnings at ($0.19) EPS.

ARWR has been the subject of a number of other reports. Jefferies Group LLC reissued a hold rating and issued a $2.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Friday, August 4th. Chardan Capital reissued a neutral rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, September 13th. ValuEngine lowered Arrowhead Pharmaceuticals from a sell rating to a strong sell rating in a research report on Friday, June 2nd. Piper Jaffray Companies reissued a hold rating and issued a $2.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Friday, July 28th. Finally, Cantor Fitzgerald reissued a hold rating and issued a $2.00 price target (up from $1.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $2.00.

Arrowhead Pharmaceuticals (ARWR) opened at 3.52 on Monday. The company’s 50-day moving average is $2.49 and its 200-day moving average is $1.89. The firm’s market capitalization is $263.20 million. Arrowhead Pharmaceuticals has a one year low of $1.20 and a one year high of $8.09.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.06. The business had revenue of $9.34 million during the quarter, compared to analyst estimates of $5.29 million. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%. Equities analysts forecast that Arrowhead Pharmaceuticals will post ($0.42) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Arrowhead Pharmaceuticals, Inc. (ARWR) Upgraded at William Blair” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.watchlistnews.com/arrowhead-pharmaceuticals-inc-arwr-upgraded-at-william-blair/1577048.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. UBS Asset Management Americas Inc. increased its position in shares of Arrowhead Pharmaceuticals by 414.7% during the 1st quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 53,500 shares during the last quarter. Virtu KCG Holdings LLC increased its position in shares of Arrowhead Pharmaceuticals by 115.6% during the 2nd quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 53,215 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Arrowhead Pharmaceuticals by 287.9% during the 1st quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company’s stock valued at $186,000 after purchasing an additional 74,776 shares during the last quarter. Teachers Advisors LLC increased its position in shares of Arrowhead Pharmaceuticals by 18.0% during the 4th quarter. Teachers Advisors LLC now owns 112,642 shares of the biotechnology company’s stock valued at $175,000 after purchasing an additional 17,201 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Arrowhead Pharmaceuticals by 144.8% during the 1st quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock valued at $278,000 after purchasing an additional 88,933 shares during the last quarter. 20.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.